Context

Fresenius agreed to acquire a 55% majority stake in mAbxience from its founding shareholders, with a contractual put/call option mechanism covering the remaining 45% of the share capital. The acquisition delivers on Fresenius Kabi's core "Broaden Biopharma" growth vector under its Vision 2026 strategy, addressing a critical gap in the division's value chain by adding flexible, single-use biologic drug substance manufacturing capacity. The transaction is expected to generate material operating and cost synergies, primarily driven by leveraging mAbxience's manufacturing capabilities for Fresenius Kabi's existing biosimilars portfolio, and to create an end-to-end integrated biopharmaceutical platform serving both internal programmes and third-party CDMO clients.

Target

mAbxience is a leading international biopharmaceutical company focused on the rapidly developing biosimilars market, founded in 2010 as the biotechnology division of Insud Pharma S.L. The company has established itself as a leader in the development and manufacturing of biological drugs, with two commercialised biosimilar products (Rituximab and Bevacizumab) and a mid-single-digit number of molecules across immunology and oncology expected to be launched globally between 2024 and 2029. mAbxience operates three state-of-the-art biologics manufacturing facilities in Spain and Argentina, supported by internal R&D laboratories, offering highly competitive production costs. In addition to its proprietary biosimilars programmes, mAbxience operates a biologics CDMO business serving third-party clients, including a contract with AstraZeneca to produce the drug substance for its COVID-19 vaccine in Latin America.